PAVmed Business Summary

PAVmed Inc. (PAVM) operates as a diversified, commercial-stage medical technology company utilizing a shared services model to advance a pipeline of subsidiaries from concept to commercialization. The company generates revenue primarily through its majority-owned subsidiaries: Lucid Diagnostics Inc. (Nasdaq: LUCD), which commercializes the EsoGuard esophageal DNA test and EsoCheck cell collection device for early cancer detection, and Veris Health Inc., a digital health entity focused on remote patient monitoring via its Cancer Care Platform and implantable physiological monitors. Following the deconsolidation of Lucid Diagnostics for accounting purposes in late 2024, PAVmed’s financial structure shifted to an equity-method investment model, though it continues to derive value from diagnostic test sales, remote monitoring service fees, and medical device licensing. Direct competitors include Guardant Health, GRAIL, and Sysmex Corporation; PAVmed distinguishes itself by focusing on the niche intersection of minimally invasive diagnostics and integrated digital health monitoring for high-risk oncology patients. The leadership team is anchored by Co-founder, Chairman, and CEO Dr. Lishan Aklog, a Harvard-trained cardiac surgeon and prolific inventor with over 35 patents who previously co-founded Vortex Medical. He is supported by President and Chief Financial Officer Dennis McGrath, who brings extensive executive experience from PhotoMedex, and Executive Vice President and COO Shaun O’Neil, who leads commercial operations across the subsidiary portfolio. The founding team also includes Vice Chairman Michael Glennon and Brian J. deGuzman, MD, both of whom possess deep pedigrees in medical device incubation through Pavilion Holdings Group. Notable institutional backing includes significant positions from First Manhattan Co., Geode Capital Management, and Jane Street Group, while the Board of Directors features industry veterans such as Ronald Sparks and Dr. Sundeep Agrawal, providing a blend of clinical expertise and private equity experience.